Journal article · 2026
Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis
New England Journal of Medicine · Published 22 October 2026 · DOI 10.1056/nejmoa2610103
In brief
“Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis” is a 2026 journal article by Jonathan Barratt and 23 co-authors, published in New England Journal of Medicine. OpenAlex counts 2 citations as of 16 November 2026, which puts it in the top 5% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 2
- Most cited in
- 2026 (2)
- Field-weighted impact
- 7.81
- References
- 25
- Authors
- 24
Abstract
BackgroundAtacicept resulted in a significantly greater reduction in the urinary protein-to-creatinine ratio than placebo in a previously published analysis of this trial, ORIGIN 3. Final prespecified efficacy results are reported here. MethodsWe randomly assigned adults with biopsy-confirmed IgA nephropathy to receive weekly subcutaneous atacicept at a dose of 150 mg or placebo. We carried out… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Barratt, J., Brenner, R. M., Barbour, S. J., Campbell, K. N., Doan, T., Eren, N., Floege, J., Fordyce, M. W., Jha, V., Khawaja, Z., Kim, B. S., Liew, A., Maes, B., Pal, A., Pecoits‐Filho, R., Phoon, R. K. S., Rizk, D. V., Suzuki, H., Tesař, V., . . . Lafayette, R. A. (2026). Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2610103
MLA 9
Barratt, Jonathan, et al. “Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis.” New England Journal of Medicine, 2026. https://doi.org/10.1056/nejmoa2610103.
Chicago
Barratt, Jonathan, Robert M. Brenner, Sean J. Barbour, Kirk Nicholas Campbell, Tom Doan, Necmi Eren, Jürgen Floege, et al. 2026. “Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis.” New England Journal of Medicine. https://doi.org/10.1056/nejmoa2610103.
Harvard
Barratt, J. et al. (2026) ‘Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis’, New England Journal of Medicine. doi:10.1056/nejmoa2610103.
IEEE
J. Barratt et al., “Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis,” New England Journal of Medicine, 2026, doi: 10.1056/nejmoa2610103.
BibTeX
@article{barratt2026atacicept,
title = {{Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis}},
author = {Barratt, Jonathan and Brenner, Robert M. and Barbour, Sean J. and Campbell, Kirk Nicholas and Doan, Tom and Eren, Necmi and Floege, Jürgen and Fordyce, Marshall W. and Jha, Vivekanand and Khawaja, Zeeshan and Kim, Beom Seok and Liew, Adrian and Maes, Bart and Pal, Atanu and Pecoits‐Filho, Roberto and Phoon, Richard K. S. and Rizk, Dana V. and Suzuki, Hitoshi and Tesař, Vladimír and Trimarchi, Hernán and Wei, Xuelian and Yu, Lixi and Zhang, Hong and Lafayette, Richard A.},
journal = {New England Journal of Medicine},
year = {2026},
doi = {10.1056/nejmoa2610103},
url = {https://doi.org/10.1056/nejmoa2610103}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- atacicept
- IgA nephropathy
- estimated glomerular filtration rate
- kidney disease progression
- eGFR slope
- urine protein-to-creatinine ratio
- subcutaneous administration
- C5a receptor
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Barratt, J., Brenner, R. M., Barbour, S. J., Campbell, K. N., Doan, T., Eren, N., Floege, J., Fordyce, M. W., Jha, V., Khawaja, Z., Kim, B. S., Liew, A., Maes, B., Pal, A., Pecoits‐Filho, R., Phoon, R. K. S., Rizk, D. V., Suzuki, H., Tesař, V., . . . Lafayette, R. A. (2026). Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2610103
How many times has this paper been cited?
2 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Jonathan Barratt, Robert M. Brenner, Sean J. Barbour, Kirk Nicholas Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Marshall W. Fordyce, Vivekanand Jha, Zeeshan Khawaja, Beom Seok Kim, Adrian Liew and 12 more.
What is the DOI of this paper?
10.1056/nejmoa2610103, permanently at https://doi.org/10.1056/nejmoa2610103. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.